Vascular endothelial growth factor inhibitors (VEGFIs) have transformed treatment paradigms for several malignancies. By ...

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne ...

Biocon Biologics, a subsidiary of India-based Biocon Ltd, said on Thursday that U.S. FDA has approved Jobevne, a biosimilar ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...

Anemia is a common condition in premature infants, particularly those at risk for retinopathy of prematurity (ROP).

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Biocon Biologics' Jobevne, a biosimilar of Avastin, approved by the FDA, expanding oncology portfolio and access to ...

The FDA has approved bevacizumab-nwgd, a biosimilar to bevacizumab, for intravenous use across multiple cancer types.

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.